SynGenSys, a fast-growing biotechnology spinout company from the University of Sheffield, has completed a successful angel-led £1.8m seed fundraise as Dr Andy Racher steps in as its Commercial Operations Director.
SynGenSys specialises in designing and constructing synthetic genetic components to advance next-generation biomedicines and biomanufacturing processes.
With over three decades of experience in the biotechnology sector, Andy brings a wealth of expertise to his new role. He has previously held numerous senior positions at Lonza Biologics, a Contract Development and Manufacturing Organisation (CDMO).
Andy’s roles at Lonza included Director of R&D IP Strategy, Associate Director within the Future Technologies Group, Head of Process Development Sciences, Acting Head of Cell Culture Process Development, and Senior Principal Scientist of Cell Culture Process Development.
Andy said: “I am delighted to be joining the SynGenSys team at such an exciting time in the company’s development, and I am looking forward to helping SynGenSys build out its market-facing commercial function.”
Professor David James, co-founder and Chief Technology Officer of SynGenSys, added: “We are very pleased to have recruited someone of Andy’s calibre to our team. His is the first of a number of appointments that the company is looking to make as we start to offer our products and services to customers across the world.”
Law firm Freeths advised SynGenSys on the seed fundraise. Commenting on Andy’s appointment, Freeths’ Corporate Partner, Peter Crawford said: “Having recently advised on SynGenSys’ successful seed fundraise, it is great to see the company making real progress and Andy’s appointment is fundamental to support that growth. I’m confident he will be a great addition to the team.”
Corporate finance advice on the fundraise was provided by Translink.
